Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

474.02 -7.14 (-1.48%)
Streaming Delayed Price Updated: 12:47 PM EST, Feb 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 Next >
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
From Vertex Pharmaceuticals
Via Business Wire
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
From Zai Lab Limited
Via Business Wire
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Reports Third Quarter 2024 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Participate in Upcoming November Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Announce Third Quarter 2024 Financial Results on November 4th
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Biotech Breakout: Stocks for Your Watchlist
The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150. 
Via MarketBeat
Topics ETFs
Vertex to Participate in Upcoming September Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England
From Vertex Pharmaceuticals
Via Business Wire
Vertex Reports Second Quarter 2024 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout. 
Via MarketBeat
Topics ETFs
Exposures COVID-19
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Announce Second Quarter 2024 Financial Results on August 1
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Participate in Upcoming June Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Jennifer Schneider Elected to Vertex Board of Directors
From Vertex Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.